Proteomics has provided powerful new insights into the complex events of the anucleate platelet and has revealed many potential protein targets in the search for suitable agents for thrombotic disease. In the present study, we summarize recent proteomic approaches to analyse specific platelet subproteomes, such as the platelet releasate, the platelet phosphotyrosine proteome and characterization of the proteins associated with membrane lipid rafts.
which can provide precise peptide masses, to complex tandem MS machines that also yield partial amino acid sequence information for unambiguous protein identification [6, 7] .
The incorporation of proteomics into functional biochemical and biological investigations has proved to be a powerful tool when applied to the complex events of the anucleate platelet, from adhesion and activation to secretion and aggregation. For an in-depth review of these studies, see [8, 9] . In the present study, we summarize recent proteomic approaches to analyse specific platelet subproteomes such as the platelet releasate, the platelet phosphotyrosine proteome and characterization of the proteins associated with membrane lipid rafts.
Characterization of the platelet releasate
Platelets contain a number of preformed, morphologically distinguishable storage granules: α-granules (some containing exosomes of endosomal origin [10] ), dense granules and lysosomes; the contents of these are released into the external milieu upon platelet activation [11] . Many of the proteins released in this manner act in an autocrine or paracrine fashion to modulate cell signalling, including the prothrombotic protein GAS-6 (growth arrest-specific gene 6) and the immune modulator, platelet basic protein [12, 13] . Furthermore, certain chemokines released by activated platelets such as platelet factor-4 have been found in atherosclerotic plaques and, through macrophage differentiation, may contribute to the inflammation that is a hallmark of the disease [14] . Therefore, since the platelet releasate contains factors that conceivably contribute to the development of atherothrombosis, we recently identified, using a proteomics approach, more than 300 proteins that were released by human platelets after thrombin activation [15] .
After verification that the supernatant fraction of thrombin-activated platelets contained known secreted proteins but contained no membrane proteins, such as α V β 3 , the releasate fraction was separated by 2-DE; then, 22 Coomassie Blue-stained protein spots were excised, proteolytically digested and identified using MALDI-TOF MS. The identified proteins included the known platelet-secreted proteins Table 1 Some of the proteins identified in the thrombinactivated platelet releasate using multi-dimensional chromatography coupled with tandem MS Spectra from the two-dimensional liquid chromatography tandem MS run were identified using the SEQUEST program and a composite mouse and human database (NCBI July 2002 release). The gene name and the number of peptides identified for these proteins are indicated. For the full list of 300 proteins, see [15] .
Name
Gene osteonectin, thrombospondin and α 1 -antitrypsin, and proteins not previously known to be released, including 14-3-3 protein ξ /δ and actin. Using a complimentary approach to 2-DE, the releasate fraction was further separated by multidimensional chromatography coupled with tandem MS. In brief, the released protein fraction from thrombinactivated platelets was digested with trypsin and the resulting peptides were separated by tandem strong cation-exchange and reverse-phase chromatography before introduction into an ion-trap mass spectrometer [5] . This approach enabled the discovery of >300 proteins, 81 of which were observed in two or three experiments (Table 1) ; 37% of these proteins were previously reported to be released from platelets, including multimerin, amyloid β protein and vitamin K-dependant protein. A further 35% was previously known to be released from other secretory cells, including β 2 -microglobulin, tubulin and 14-3-3ξ from dendritic cells [16] and cyclophilin A from smooth-muscle cells [17] . The remaining proteins have not been reported as released from any cell type and they include many proteins of unknown function that were mapped to expressed sequence tags. Three proteins, secretogranin-III (a potential monocyte chemoattractant precursor), cyclophilin A (a vascular smoothmuscle cell growth factor) and calumenin (an inhibitor of γ -carboxylation by targeting the cofactor vitamin K epoxide reductase), not previously attributed to platelets, were examined further since they are of potential interest in the pathogenesis of atherosclerosis. It was confirmed that these proteins are localized in platelets and are released upon activation. Furthermore, although absent from normal vasculature, these Characteristic tyrosine-phosphorylated proteomes for (a) resting and (b) 0.1 unit thrombin-activated human platelets were isolated using the monoclonal antibody 4G10 and then separated by 2-DE. pI 3-10 IPGphor TM strips were used in the first dimension and the gels were silver-stained.
proteins were identified in human atherosclerotic lesions, which also stained for the platelet-specific proteins integrin αIIbβ3 and platelet factor-4. Therefore these and other proteins released from platelets may contribute to atherosclerosis and to the thrombosis that complicates the disease. Indeed, such secreted proteins may prove suitable as therapeutic targets, given their extracellular localization, without the risk of bleeding that complicates direct inhibition of platelet activation.
Analysis of the phosphotyrosine proteome
Signalling cascades, including those in the platelet, are controlled both positively and negatively by phosphorylation [18] . To date, many protein and lipid kinases, phosphatases, phospholipases and GTPases have been shown to be tyrosine-phosphorylated during platelet activation and spreading [18] , including ERK2 (extracellular-signal-regulated kinase 2) and cytosolic tyrosine kinases, e.g. Syk and Src [19] [20] [21] . However, it is probable that additional protein phosphorylation events contribute to the dynamic changes involved in platelet activation, and aggregation and proteomics studies are a novel approach in providing an overview of these phosphorylation cascades. For a comprehensive review of all the platelet phosphoproteomics studies, see [8, 9] .
We have used a proteomic strategy to examine tyrosine phosphorylation upon thrombin activation of platelets, with the aim of identifying novel signalling events [22] . Dynamic phosphotyrosine changes were enriched by immunoprecipitation using the monoclonal antibody 4G10, allowing the capture of relatively low-abundance proteins, and the tyrosinephosphorylated proteome from both resting and 0.1 unit thrombin-activated human platelets was separated by 2-DE ( Figure 1 ). In combination with MALDI-TOF MS and immunoblotting, 67 differences were reproducibly highlighted between control and thrombin-activated platelets and several of these proteins were identified, including FAK, Syk, mitogen-activated protein kinase (MAPKKK) and activin
Figure 2 MS analysis of DRM-associated proteins
Tandem MS spectrum of the T8 tryptic peptide of the human protein tyrosine kinase p60 src, which was found associated with the DRM fraction in platelets. A 60 kDa band was excised from a one-dimensional SDS/polyacrylamide gel (colloidal Coomassie Brilliant Blue-stained) and the proteins were digested with trypsin. The resulting peptides were extracted from the gel and analysed in data-dependent acquisition mode on a QTOF Ultima API (Micromass, Manchester, U.K.). Spectra were processed in batch mode and searched against an in-house copy of SWISS-PROT Protein Sequence database using ProteinLynx Global Server 1.1 (Micromass). Protein tyrosine kinase p60 src was one of the eight proteins identified in this particular band. Seven tandem MS spectra for src were found, yielding total sequence coverage of 18.1%. Y-and b-fragment mass assignments are indicated in red and blue respectively.
receptor-like kinase 4, which contain the known tyrosine phosphorylation motifs DXXY and EXXY [22] .
Recently, we extended this analysis and have identified NMMHC-IIA (non-muscle myosin heavy-chain type IIA), which was not previously known to be regulated by tyrosine phosphorylation in platelets. A marked increase in tyrosine phosphorylation of NMMHC-IIA was detected within 15 s of stimulation with thrombin, which became diminished by 180 s. Moreover, this phosphorylation event appeared to be reversible, since treatment of platelets with abciximab, an αIIbβ3 antagonist, at a concentration that blocked platelet aggregation, prevented this dephosphorylation. We found that the NMMHC-IIA tyrosine phosphorylation was a feature of many agonists, and dephosphorylation was, in each case, triggered by engagement of αIIbβ3. A previously undescribed serine phosphorylation site was mapped to the C-terminus (position 1943) of NMMHC-IIA, whereas bioinformatics analysis revealed a strong candidate for tyrosine phosphorylation at position 158. This protein appears to be of particular importance to platelet function since five autosomal-dominant disorders including the May-Hegglin anomaly and Sebastian syndromes are all caused by mutations in the NMMHC-IIA gene and, akin to the Bernard Soulier syndrome, these pathologies are characterized by giant platelets and thrombocytopenia [23] [24] [25] . Our results suggest that NMMHC-IIA is also involved in the activity of adult platelets.
Characterization of the proteins associated with membrane lipid rafts
Lipid rafts are specialized membrane regions, consisting of dynamic assemblies of cholesterol and sphingolipids [26] .
These domains are rich in dynamic multi-protein complexes [26a] that have been suggested to play a role in the regulation of platelet activation processes, particularly those mediated by GPVI (glycoprotein VI) and GPIb/IX/V [27] [28] [29] [30] [31] . Furthermore, several platelet signalling proteins have been shown to be DRM (detergent-resistant membrane)-associated, including CD36 [32] , the Src-family kinases Lck and Fyn, the adapter protein LAT (linker for activation of T cells) [33] and, upon binding of VWF (von Willebrand factor), GPIb/IX/V and GPIbα [28] .
The standard biochemical method used to isolate rafts and their associated proteins makes use of their insolubility in non-ionic detergents at 4
• C. These DRM-associated proteins float in low-density fractions from sucrose gradients [29] and, recently, proteomic studies have identified proteins associated with the DRM fraction of other cells [34] [35] [36] [37] . Thus, to elucidate the role of these domains in platelet function, we have undertaken a proteomic profiling of the proteins associated with 1% Triton X-100 DRMs from control and VWFactivated platelets using liquid chromatography coupled with tandem MS.
More than 150 proteins were identified, including characteristic raft proteins such as flotillin-1 and many proteins that were not previously described as DRM-associated, including the Ras GTPase-activating protein 3 and the small GTPase rap 1b. The high level of signalling and trafficking proteins identified, including src ( Figure 2 ) and several proteins novel to the platelet, e.g. rab 5, rab 8 and syntaxin 11, implicates DRMs as concentrating platforms not only in the critical platelet function of activation but also, for the first time, in secretion. Furthermore, platelet activation resulted in the translocation of several proteins into or out of the DRM fraction, with proteins recruited upon VWF activation, including GPIbα, glucose transporter 14 and CLP-36 (C-terminal LIM domain protein 36). As an adapter protein, CLP-36 may interact with GPIb/IX/V through another DRMassociated protein, namely α-actinin, thereby facilitating signalling through lipid rafts [38] . Such changes in the proteome of platelet DRMs upon activation suggest that these dynamic membrane domains may act as concentrating platforms that co-cluster receptors and signalling molecules, thus ensuring efficient, co-ordinated platelet activation and secretory processes. Targeting of proteins recruited to platelet DRMs upon activation may represent a novel therapeutic strategy in the prevention of thrombosis.
The future
Study of the expression, localization, modification and interactions of platelet proteins, as well as monitoring the changes that could be the cause or a consequence of disease processes, will reveal a wealth of information on platelets and the molecular basis of thrombotic disease. Furthermore, future application to platelet biology of the recent advancements in proteomic methods such as automated protein quantification using stable-isotope labels coupled with tandem MS and affinity tag purification of protein complexes [39] [40] [41] [42] [43] offers a more exciting prospect. In short, proteomic approaches will offer unprecedented opportunities to unlock the mysteries of platelet biology and enable new diagnostic and therapeutic strategies for thrombotic disease. 
